Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection

• Status: Unknown status
• Trial end date: 2017-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the therapeutic evaluation of combination therapy with aspirin and salvianolate injection based on the population pharmacokinetics and TEG.A prospective, multicenter, randomized, controlled clinical trial is used.A total of 120 patients will be recruited and will be divided into three groups,respectively salvianolate injection group,aspirin group and salvianolate injection and aspirin group，and the course of treatment is 10 days.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: China Academy of Chinese Medical Sciences
• Collaborators: General Hospital of Beijing PLA Military Region; Guang'anmen Hospital of China Academy of Chinese Medical Sciences; Guangdong Provincial Hospital of Traditional Chinese Medicine; Xiyuan Hospital of China Academy of Chinese Medical Sciences
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Patient age 35-75 years old

• Grade II diagnostic criteria for chronic stable angina pectoris

• Diagnostic criteria of blood stasis type

• Signed informed consent

Exclusion Criteria:

• Drug allergy to the test

• There is a family or personal history of hemorrhagic disease

• Platelet count < 100 * nine times square 10/L or > 450 *nine times square 10/L

• Hemoglobin < 90g/L

• ALT, AST higher than the upper limit of 2 times, BUN, Cr higher than the upper limit

• Drugs such as the use of clopidogrel, clopidogrel, Hua Falin or heparin in the last 2 weeks to take blood circulation drugs or other antiplatelet, anticoagulant or non steroidal anti-inflammatory drugs

• Heart failure three degrees, two degrees in patients with heart failure

• A history of trauma or surgery in the past 2 weeks

• Combined coronary heart disease myocardial infarction and cerebral blood vessels, liver, kidney, hematopoietic system severe primary disease, malignant tumor, mental disease patients, as well as hyperthyroidism, cervical spondylosis, stomach and esophageal reflux and other patients with chest pain

• Organ transplantation, AIDS, long-term use of immunosuppressive agents and other immune deficiency

• Pregnant or lactating women

• Other clinical trial participants who are taking part in the evaluation of the results of this study